Aaron Lorenzo

IPO Trifecta: CancerVax, Genitope Myogen All Price Public Offerings

Oct. 31, 2003

A trio of biotech IPOs priced in succession, but the public money appears to be flowing conservatively, some industry observers think. (BioWorld Today)

Now With Full Rights, Chiron Plans Tifacogin CAP Phase III

Oct. 31, 2003

By Aaron Lorenzo

Now With Full Rights, Chiron Plans Tifacogin CAP Phase III

Oct. 31, 2003

By Aaron Lorenzo

IPO Trifecta: CancerVax, Genitope Myogen All Price Public Offerings

Oct. 31, 2003

By Aaron Lorenzo

A trio of biotech IPOs priced in succession, but the public money appears to be flowing conservatively, some industry observers think. (BioWorld Today)